Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedMay 27, 2026
DataAggregated Company Financials
Companies549
  • 7D2.9%
  • 3M-4.9%
  • 1Y33.0%
  • YTD1.9%

Over the last 7 days, the Biotech industry has risen 3.1%, driven by gains from Gilead Sciences of 2.5%. In the last 12 months, the industry was up 35%. Looking forward, earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 27 May 2026US$1.3tUS$170.0b-US$12,287,916,494.2216.2x-105x7.6x
Fri, 24 Apr 2026US$1.3tUS$166.2b-US$11,939,363,270.3617.4x-111.6x8x
Sun, 22 Mar 2026US$1.3tUS$169.3b-US$15,178,198,976.9716.7x-82.7x7.4x
Tue, 17 Feb 2026US$1.3tUS$168.9b-US$12,913,326,628.3422.2x-103.4x7.9x
Thu, 15 Jan 2026US$1.2tUS$163.5b-US$15,154,501,733.5620.7x-80.9x7.5x
Sat, 13 Dec 2025US$1.2tUS$163.7b-US$15,616,357,960.0119x-78.2x7.5x
Mon, 10 Nov 2025US$1.1tUS$163.6b-US$15,730,430,581.7417x-71.8x6.9x
Wed, 08 Oct 2025US$1.1tUS$163.4b-US$18,202,969,064.3416.6x-62.2x6.9x
Fri, 05 Sep 2025US$1.1tUS$163.5b-US$18,341,252,720.1115.5x-58.6x6.6x
Sun, 03 Aug 2025US$1.0tUS$158.4b-US$20,947,422,497.0215.8x-48.4x6.4x
Tue, 01 Jul 2025US$927.2bUS$156.0b-US$23,839,320,142.0917.5x-38.9x5.9x
Thu, 29 May 2025US$918.0bUS$155.9b-US$24,119,232,490.9815.9x-38.1x5.9x
Sat, 26 Apr 2025US$795.8bUS$119.2b-US$31,094,794,492.8220.1x-25.6x6.7x
Mon, 24 Mar 2025US$827.4bUS$118.6b-US$36,836,383,348.6920.4x-22.5x7x
Wed, 19 Feb 2025US$842.4bUS$116.6b-US$36,830,915,932.5217.4x-22.9x7.2x
Fri, 17 Jan 2025US$951.1bUS$149.4b-US$26,288,384,920.3117.4x-36.2x6.4x
Sun, 15 Dec 2024US$991.8bUS$150.0b-US$26,493,336,471.9416.6x-37.4x6.6x
Tue, 12 Nov 2024US$1.1tUS$149.6b-US$27,256,722,122.3916.2x-40.7x7.4x
Thu, 10 Oct 2024US$885.2bUS$113.1b-US$35,888,682,575.9519.9x-24.7x7.8x
Sat, 07 Sep 2024US$873.8bUS$113.1b-US$35,668,533,175.3222.2x-24.5x7.7x
Mon, 05 Aug 2024US$1.2tUS$165.8b-US$32,343,076,510.8425.9x-37x7.2x
Wed, 03 Jul 2024US$1.1tUS$164.4b-US$27,942,623,021.7228.6x-41.1x7x
Fri, 31 May 2024US$1.1tUS$164.6b-US$26,676,846,840.1227.1x-41.7x6.8x
Sun, 28 Apr 2024US$1.1tUS$164.6b-US$27,372,800,636.0922.6x-39.1x6.5x
Tue, 26 Mar 2024US$1.2tUS$164.3b-US$23,900,589,317.2321.6x-48.6x7.1x
Thu, 22 Feb 2024US$1.2tUS$168.4b-US$20,682,314,391.8813.8x-55.7x6.8x
Sat, 20 Jan 2024US$1.4tUS$204.8b-US$22,506,538,466.0018.5x-63.3x7x
Mon, 18 Dec 2023US$1.4tUS$204.7b-US$22,123,285,336.0019.2x-61x6.6x
Wed, 15 Nov 2023US$1.2tUS$204.7b-US$22,084,019,583.0018.8x-54.5x5.9x
Fri, 13 Oct 2023US$1.3tUS$207.3b-US$13,087,317,004.0016.7x-97.1x6.1x
Sun, 10 Sep 2023US$1.3tUS$207.5b-US$12,633,744,533.0017.4x-101x6.1x
Tue, 08 Aug 2023US$1.3tUS$206.8b-US$12,334,291,943.0015.3x-101.9x6.1x
Thu, 06 Jul 2023US$1.1tUS$186.2b-US$16,071,351,382.0013.4x-70.3x6.1x
Sat, 03 Jun 2023US$1.1tUS$185.9b-US$16,006,497,567.0011.4x-71.1x6.1x
Price to Earnings Ratio

-71.1x


Total Market Cap: US$1.1tTotal Earnings: -US$16,006,497,567.00Total Revenue: US$185.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -57.8x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 7.6x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 2.9% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market2.46%
Healthcare1.39%
Biotech2.94%
Biotech2.94%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GILD Gilead SciencesUS$133.732.5%
+US$4.0b		22.6%PE18x
AMGN AmgenUS$335.941.6%
+US$2.8b		20.2%PE23.2x
RVMD Revolution MedicinesUS$154.895.2%
+US$1.6b		318.9%PB22x
IMVT ImmunovantUS$33.8328.7%
+US$1.6b		136.7%PB8.1x
ROIV Roivant SciencesUS$29.675.2%
+US$1.1b		175.7%PS2583.2x

Latest News

CGON
US$61.89
CG Oncology
7D
-2.2%
1Y
142.5%
AMGN
US$335.94
Amgen
7D
1.6%
1Y
20.2%
ROIV
US$29.67
Roivant Sciences
7D
5.2%
1Y
175.7%
ABBV
US$213.12
AbbVie
7D
-0.3%
1Y
14.8%
IMVT
US$33.83
Immunovant
7D
28.7%
1Y
136.7%
Seeking Alpha • May 25

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential

Summary Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts. IMVT-1402 is particularly promising because it could work across several indications. I think it could become a franchise asset, but future readouts still have to confirm that. Overall, I think IMVT is a viable speculative “Buy” at these levels, despite its inherent clinical trial risks. IMVT-1402’s potential as a broad FcRn platform makes it worth the risk. Read the full article on Seeking Alpha
BNTX
US$92.25
BioNTech
7D
5.1%
1Y
-6.4%
RVMD
US$154.89
Revolution Medicines
7D
5.2%
1Y
318.9%
SMMT
US$17.00
Summit Therapeutics
7D
7.3%
1Y
-33.7%
TWST
US$64.87
Twist Bioscience
7D
31.1%
1Y
120.6%
ONC
US$302.44
BeOne Medicines
7D
-2.0%
1Y
25.8%
Narrative Update • May 23

ONC: Hematology Franchise And Upcoming Trial Readouts Will Support Future Upside

Analysts lifted the price target on BeOne Medicines by $3 to $411.51, as updated models reflect the recent FDA accelerated approval for sonrotoclax in relapse and refractory mantle cell lymphoma, along with ongoing combination trials and a higher assumed profit margin that more than offsets slightly lower projected revenue growth and a reduced future P/E multiple. Analyst Commentary Recent research on BeOne Medicines centers on how the first FDA accelerated approval for sonrotoclax and the outlook for Brukinsa affect valuation, growth expectations, and perceived execution risk.
GILD
US$133.73
Gilead Sciences
7D
2.5%
1Y
22.6%
ADMA
US$8.15
ADMA Biologics
7D
-5.6%
1Y
-59.0%
STRO
US$27.38
Sutro Biopharma
7D
-13.5%
1Y
190.0%
PTCT
US$67.65
PTC Therapeutics
7D
-3.8%
1Y
41.3%
Narrative Update • May 19

PTCT: Early Neurology Execution Will Drive Huntington Progress Toward Bullish 2026 Outlook

Analysts have nudged their average price target on PTC Therapeutics higher, from about $88 to roughly $91, reflecting updated models that factor in stronger projected revenue growth, higher expected profit margins, and a lower assumed discount rate, alongside Street research that has largely raised or reaffirmed positive price targets following recent Q4 results and Sephience launch commentary. Analyst Commentary Recent Street research on PTC Therapeutics reflects a mix of optimism around the Sephience launch and revenue outlook, alongside some caution on execution risks and prior franchises.
BCRX
US$8.47
BioCryst Pharmaceuticals
7D
-3.4%
1Y
-21.5%
Narrative Update • May 16

BCRX: Astria Integration And Licensing Deal Will Support Hereditary Angioedema Expansion

Analysts have nudged their average price target on BioCryst higher by low single digits in recent weeks, citing reiterated long-term revenue goals following the Astria Therapeutics acquisition, ongoing confidence in Orladeyo and navenibart sales potential, and steadier expectations for future profitability and P/E levels. Analyst Commentary Recent research has leaned constructive on BioCryst, with several bullish analysts adjusting their price targets upward and reaffirming confidence in the company’s long term revenue framework following the Astria Therapeutics acquisition.
ANAB
US$57.77
AnaptysBio
7D
-3.3%
1Y
187.0%